Article

The effect of metformin and thiazolidinedione use on lung cancer in diabetics

BMC Cancer (Impact Factor: 3.32). 09/2012; 12(1):410. DOI: 10.1186/1471-2407-12-410
Source: PubMed

ABSTRACT Background
Metformin and the thiazolidinediones (TZDs) may have a protective effect against the development of lung cancer.

Methods
Patients with diabetes mellitus (DM) were identified from the electronic medical records of the Cleveland Clinic. Diabetics with lung cancer were identified then verified by direct review of their records. Control subjects were matched with cancer subjects 1:1 by date of birth, sex, and smoking history. The frequency and duration of diabetic medication use was compared between the groups. The cancer characteristics were compared between those with lung cancer who had and had not been using metformin and/or a TZD.

Results
93,939 patients were identified as having DM. 522 lung cancers in 507 patients were confirmed. The matched control group was more likely to have used metformin and/or a TZD (61.0% vs. 41.2%, p < 0.001 for any use; 55.5% vs. 24.6%, p < 0.001 for >24 months vs. 0–12 months). In the group with lung cancer, those who had used metformin alone had a different histology distribution than those who received neither metformin nor a TZD, were more likely to present with metastatic disease (40.8% vs. 28.2%, p = 0.013), and had a shorter survival from the time of diagnosis (HR 1.47, p < 0.005).

Conclusions
The use of metformin and/or the TZDs is associated with a lower likelihood of developing lung cancer in diabetic patients. Diabetics who develop lung cancer while receiving metformin may have a more aggressive cancer phenotype.

Download full-text

Full-text

Available from: Anil K Jain, Jan 28, 2014
1 Follower
 · 
157 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Metformin, a biguanide, is a commonly administered drug for the management of type 2 diabetes mellitus. The drug received a lot of recognition, when retrospective studies proved metformin-associated reduction in cancer risk. Metformin has potential anti cancer effects and an ability to suppress tumor growth both in vitro and in vivo. Activation of LKB1/AMPK pathway and cancer stem destruction along with cell cycle arrest and apoptosis induction is the proposed mechanisms of anti cancer potential of metformin. Nanotechnology approaches have also been adopted for metformin delivery to cancer cells. This review directs on the application of metformin for the therapy of various cancers and also the different pathways responsible for the metformin derived anti cancer effect. It also focuses on the pharmacological applications of the drug and the nanotechnology approaches for metformin delivery.
    Current Cancer Drug Targets 10/2014; 14(8). DOI:10.2174/1568009614666141020105502 · 3.58 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Rational: Prior studies have shown an anticancer effect of metformin in patients with breast and colorectal cancer. It is unclear, however, whether metformin has a mortality benefit in lung cancer. Objectives: To compare overall survival of diabetic patients with stage IV non-small cell lung cancer (NSCLC) taking metformin versus those not on metformin. Methods: Using data from the Surveillance, Epidemiology and End Results registry linked to Medicare claims, we identified 750 diabetic patients 65-80 years of age diagnosed with stage IV NSCLC between 2007 and 2009. We used propensity score methods to assess the association of metformin use with overall survival while controlling for potential confounders. Measurements and Main Results: Overall, 61% of patients were on metformin at time of lung cancer diagnosis. Median survival in the metformin group was five months, compared to three months in patients not treated with metformin (p<0.001). Propensity score analyses showed that metformin use was associated with a statistically significant improvement in survival (hazard ratio: 0.80, 95% confidence interval 0.71 to 0.89), after controlling for sociodemographics, diabetes severity, other diabetes medications, cancer characteristics, and treatment. Conclusions: Metformin is associated with improved survival among diabetic patients with stage IV NSCLC suggesting a potential anticancer effect. Further research should evaluate plausible biological mechanisms as well as test the effect of metformin in prospective clinical trials.
    American Journal of Respiratory and Critical Care Medicine 12/2014; 191(4). DOI:10.1164/rccm.201407-1395OC · 11.99 Impact Factor
  • Source